Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Phase 2 Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreated Multiple Myeloma
Brief Summary: The purpose of this study is to evaluate safety and effectiveness of CNTO 328 (siltuximab) when it is administered together with velcade-melphalan-prednisone (VMP) in comparison with VMP alone in participants with multiple myeloma (a type of cancer that affects the blood and bone marrow).


Options:
A: Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): N/A
B: Arm Label: Part 1: VMP+Siltuximab 11 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Siltuximab11 mg/kg, Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Arm Label: Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Siltuximab 8.3 mg/kg or 11 mg/kg, Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Arm Label: Part 2, Arm B: VMP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade (bortezomib), Drug: Melphalan, Drug: Prednisone | Intervention Type: DRUG; Name: Siltuximab11 mg/kg; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Siltuximab 8.3 mg/kg or 11 mg/kg; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 1: VMP+Siltuximab 11 mg/kg | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg | Intervention Type: DRUG; Name: Velcade (bortezomib); Assigned to Arm(s): Part 2, Arm B: VMP | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Part 2, Arm B: VMP | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Part 2, Arm B: VMP
C: Arm Label: Arm I (thalidomide); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Melphalan, Drug: Prednisone, Other: Quality-of-Life Assessment, Drug: Thalidomide | Arm Label: Arm II (lenalidomide); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Lenalidomide, Drug: Melphalan, Drug: Prednisone | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Arm II (lenalidomide) | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm I (thalidomide), Arm II (lenalidomide) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (thalidomide) | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Arm I (thalidomide)
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone, Drug: lenalidomide | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone, Other: placebo | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II

Answer: B